RxDoctor Payments Data

Cindy Varga, MD

Hematology · Charlotte, NCNPI 1043555139

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,811 of the $20,968 with a category attached, or 94.5%. 8 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 43.0% of the total. 2025 is the largest year on record at $10,325, 8.6 times the $1,200 reported in 2021.

$20,968in general payments, 2019–2025

Across 30 payments — averaging $698.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$9K
  • Janssen Global Services, LLC$5K
  • Sanofi$3K
  • Legend Biotech USA Inc.$2K
  • Adaptive Biotechnologies Corporation$1K
  • Johnson & Johnson$665
  • plus $154 from 2 others
$317,122in research payments, 2019–2025

Across 42 payments — averaging $7550.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$242K
  • Janssen Scientific Affairs, LLC$52K
  • AbbVie$23K

What the payments were for

  • Consulting fees$19,81194%
  • Food & beverage$1,1576%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,968 in reported general payments places this provider in the 55th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,449
Medicare patients
106
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax32$398,502
BrukinsaZanubrutinib11$155,782
EliquisApixaban14$8,499
Acyclovir83$944
Dexamethasone37$804
Gabapentin29$346
Duloxetine Hcl18$183
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$149
Ondansetron Hcl17$77
Tramadol Hcl19$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$8,49914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 hematology providers in North Carolina.

Other hematology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →